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ABSTRACT 
Background: Accurate determination of Mg status is important for improving nutritional 
assessment and clinical risk stratification.  
Objective: We aimed to quantify the overall responsiveness of Mg biomarkers to oral Mg 
supplementation among adults without severe diseases and their dose- and time-responses using 
available data from randomized controlled trials (RCTs). 
Methods: We identified 48 Mg supplementation trials (n=2,131) through searches of MEDLINE 
and the Cochrane Library up to November 2014. Random-effects meta-analysis was used to 
estimate weighted mean differences of biomarker concentrations between intervention and 
placebo groups. Restricted cubic splines was used to determine the dose- and time-responses of 
Mg biomarkers to supplementation.  
Results: Among the 35 biomarkers assessed, serum, plasma, and urine Mg were most commonly 
measured. Elemental Mg supplementation doses ranged from 197 to 994 mg/d. Trails ranged 
from 3 wk-5 y (median: 12 wk). Mg supplementation significantly elevated circulating Mg by 
0.04 mmol/L (95% CI: 0.02, 0.06) and 24-h urine Mg excretion by 1.52 mmol/24h (95% CI: 
1.20, 1.83) as compared with placebo. Circulating Mg concentrations and 24-h urine Mg 
excretion responded to Mg supplementation in a dose- and time-dependent manner, gradually 
reaching a steady state at doses of 300 mg/d and 400 mg/d, or after approximately 20 wk and 40 
wk, respectively (all P-nonlinearity ≤0.001). The higher the circulating Mg concentration at 
baseline, the lower the responsiveness of circulating Mg to supplementation, and the higher the 
urinary excretion (all P-linearity <0.05). In addition, RBC Mg, fecal Mg, and urine calcium were 
significantly elevated by Mg supplementation compared to placebo (all P-values < 0.05), but 
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there is insufficient evidence to determine their responses to increasing Mg doses.  
Conclusions: This meta-analysis of RCTs demonstrated significant dose- and time-responses of 
circulating Mg concentration and 24-h urine Mg excretion to oral Mg supplementation.     
Keywords: Mg status, Mg biomarkers, circulating and urine Mg, meta-analysis, randomized 
controlled trial. 
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INTRODUCTION 1 
Magnesium (Mg) is an essential cofactor in hundreds of enzymatic reactions in the human 
body (1). Mg deficiency or insufficiency, as defined by low circulating Mg concentrations, have 
been associated with a variety of chronic diseases, especially cardiometabolic diseases (2-4). Mg 
is found in whole grains, green leafy vegetables, legumes, and nuts (2), but is substantially lost 
during food refining and processing (3, 4). Mg intake is suboptimal in the US general population 
(5, 6), particularly among adolescent females, adult females, and the elderly; it is estimated that 
70% of the elderly American population has a total Mg intake below the estimated average 
requirement (EAR) (7). Mg is currently included in the list of shortfall nutrients in the 2015 
Dietary Guidelines Advisory Committee Report (DGAC) (8).  
Accurate assessment of Mg status is crucial for clinical evaluation of Mg deficiency and 
associated health endpoints (9). Although accumulating epidemiological evidence suggests 
significant associations between low circulating (serum/plasma) Mg concentrations or urinary 
Mg excretion and cardiometabolic diseases (10, 11), it remains unclear whether and to what 
extent measurements of circulating or urine Mg concentrations are modifiable. Further, the 
effects of Mg supplementation on related nutritional biomarkers, such as calcium (Ca2+) and 
parathyroid hormone (PTH) is unclear.          
To comprehensively assess the responsiveness of Mg biomarkers and Mg-related biomarkers 
to oral Mg supplementation, we conducted a meta-analysis of randomized controlled trials 
                                                          
1 AHRQ: Agency for Healthcare Research & Quality; Ca: Calcium; CI: Confidence Interval; CVD: Cardiovascular 
Disease; DGAC: Dietary Guidelines Advisory Committee Report; DRIs: Dietary Reference Intakes; EAR: 
Estimated Average Requirement; IV: Intravenous; Mg: Magnesium; MeSH: Medical Subject Headings; PTH: 
Parathyroid Hormone; PRA: Plasma Renin Activity; PRISMA: Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses; RCTs: Randomized Controlled Trials; S/WMD: Standardized/Weighted Mean Difference; SD: 
Standard Deviation; 25(OH)D: 25-hydroxyvitamin D. 
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(RCTs), to assess their dose- and time-responses to Mg supplementation. In addition, we 
explored potential sources of between-study heterogeneity by pre-specified factors that may 
influence Mg status responsiveness, such as age, sex, ethnicities, baseline Mg status, 
cardiometabolic health status (diabetes, hypertension, or cardiovascular disease), Mg 
formulation, trial sample size, and quality.  
METHODS 
Search strategy 
We followed PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-
Analyses) guidelines for meta-analyses of RCTs (12). Searches were conducted in MEDLINE 
and the Cochrane Library up to November 1, 2014. The words of “magnesium”,  “Mg”, 
“supplementation”, “supplement”, “intervention”, “depletion”, “randomized controlled trial”, 
“randomized clinical trial”, “randomized trial”, “controlled trial”, and “clinical trial” were used 
in article texts and MeSH (Medical Subject Headings) terms in searches. We also manually 
searched additional eligible trials from the references of relevant original or review papers. All 
searches were limited to articles published in English.  
Selection criteria 
We included RCTs of oral Mg supplementation in adults, which evaluated Mg biomarkers at 
baseline and after the intervention. Exclusion criteria are listed as follows: 1) studies involving 
pregnant or lactating women; 2) non-randomized, open-label, or uncontrolled studies; and 3) 
studies of patients with malignancy, severe anemia, severe infectious disease, severe liver or 
renal diseases, and other severe illnesses, as these disease conditions might directly or indirectly 
affect normal Mg metabolism. Studies that used combination supplements with Mg in the 
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intervention group were eligible only if the same combined supplements without Mg were 
included in the control group. Trials comparing multiple micronutrients containing Mg to 
placebo/blank controls were ineligible.  
Study selection 
Two authors (X Zhang and Y Song) independently examined the title and abstract of each 
article to remove irrelevant and duplicated results first. Then, any articles deemed potentially 
eligible underwent a full-text review and their eligibilities were assessed based on the same 
inclusion and exclusion criteria. Any discrepancies were resolved through discussion. 
Data extraction 
From each included study, we extracted available data on first author’s name, year of 
publication and country, sex, mean age or age range, number of participants, comorbidities, 
combination therapy, baseline dietary Mg level, study design, trial duration, formulation and 
dose of Mg supplements, types of Mg biomarkers assessed, and means and standard deviations 
(SD) of biomarkers in both Mg and control groups before and after supplementation.  
      One study compared multiple dose intervention groups with a single placebo or control 
group. To avoid correlation error and multiple comparisons, we divided the shared control group 
into 2 independent small groups with the means and SDs weighted by the corresponding sample 
sizes of intervention groups (13). If repeated measures of Mg biomarker at several time points 
were reported in a single trial, the values at the end of the study were selected for overall meta-
analysis; however, both were included in subgroup analyses when estimates were stratified into 
separate groups by pre-specified factors.  
Assessment of risk of bias 
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Trial quality was evaluated according to the Agency for Healthcare Research & Quality 
(AHRQ) criteria for quality assessment of RCTs (14, 15). The evaluation criteria include 
adequate sequence generation for randomization, allocation concealment, blinding of outcomes 
assessors, similarity of groups at baseline, selective reporting, incomplete outcome data, and 
description of losses and exclusions. Each study was judged to be of either high, low, or unclear 
risk for each criterion. In order to evaluate the potential confounding effect from trial quality, we 
also calculated a 5-item Jadad Score (16, 17) and rated each individual trial as being of either 
low (< 4) or high quality (≥ 4). 
Statistical methods 
The primary measures of interest were changes in the concentrations of Mg biomarkers in 
response to Mg supplementation. The secondary outcomes were changes in the concentrations of 
indirect but Mg status-related biomarkers, including serum calcium, potassium, PTH, and 
vitamin D, if available. To evaluate the overall responsiveness of biomarkers, we compared the 
mean changes between treatment and placebo groups, calculated as weighted mean differences 
(WMDs) and 95% CIs using a random-effects meta-analysis model (18). Standardized mean 
differences (SMDs) were estimated only when it was difficult to standardize the measure scales 
of data from individual studies. We calculated the WMDs for serum and plasma Mg 
concentrations separately, and found similar magnitude and patterns of these responses. Thus, we 
analyzed and presented circulating Mg concentrations by pooling the results of serum and 
plasma Mg concentrations from independent trials. Urine Mg was measured as 24-h urine Mg 
excretion (mmol/24h) in this study. We examined between-study heterogeneity by Q test and I2 
statistics, with I2 ≥ 75% indicating high heterogeneity. 
To explore potential sources of heterogeneity and assess robustness of the results, we 
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conducted subgroup analyses stratified by age, sex, ethnicities, baseline Mg status, 
cardiometabolic health status (diabetes, hypertension, or cardiovascular disease), Mg 
formulation, trial sample size, and quality. Additionally, sensitivity analyses were conducted by 
removing one study at a time to check if a single study substantially influenced the summary 
measure of each meta-analysis. We examined possible publication bias by visual inspection of 
funnel plots and formal tests, including Begg’s adjusted rank correlation test and Egger’s 
regression asymmetry test (19, 20).  
Restricted cubic spline regression analyses were performed to assess the dose- and time- 
responses relations of biomarkers to Mg supplementation. For each study, we calculated 
restricted cubic splines with three fixed knots at 10%, 50%, and 90% percentiles based on the 
overall distributions of doses and trial durations of all included studies. Then we combined the 
estimates to depict dose- and time-dependent linear or nonlinear relations of Mg biomarker 
responsiveness to Mg supplementation (21, 22).  
A two-tailed P < 0.05 was considered statistically significant. Stata (Version 13; StataCorp, 
College Station, TX) was used for all statistical analyses. 
RESULTS  
Our systematic search initially identified 1,766 articles (Figure 1). Among them, 38 articles 
met inclusion criteria, consisting of 48 RCTs assessing 35 Mg biomarkers (Supplemental Table 
1). A total of 2,131 adult participants were studied: 1,105 in the randomly assigned Mg 
supplement groups and 1,026 in the placebo groups. Trial durations ranged from 3 wk to 5 y 
(median: 12 wk). Participants had a median age of 47 y (range: 17–85 y); 56% of participants 
were women, and 58.4% were considered healthy. Doses of Mg supplements varied widely from 
197 to 994 mg/d elemental Mg (median: 360 mg/d). Two major types of Mg salts, organic (50% 
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trials) and inorganic Mg salts, were administered based on 9 Mg formulations. Among them, the 
six organic formulations were Mg orotate, Mg citrate, Mg aspartate, Mg gluconate, Mg pidolate, 
and Mg lactate; and the three inorganic formulations were Mg(OH)2, MgO, and MgCl2.  
Of 35 identified biomarkers, serum and plasma Mg were most commonly used (41 trials), 
followed by 24-h urine Mg (24 trials), red blood cell Mg (9 trials), and ionized Mg (5 trials). 
Only a few articles evaluated Mg status in other compartments, such as muscle, intracellular, 
saliva, hair, feces, and brain tissue (Figure 1). Additionally, 16 publications provided data on 
biomarkers indirectly related to Mg status, including calcium, potassium, and sodium 
concentrations in serum/plasma or urine, serum Ca/Mg ratio, PTH, and plasma renin activity 
(PRA).  
Circulating Mg concentrations  
Circulating Mg (serum or plasma) was most common biomarker assayed (41 trials), 
accounting for 87% of eligible articles (941 participants in treatment and 953 in control arms). 
After Mg supplementation at a median dose of 365 mg/d (range: 197–994 mg/d) for 12 wk 
(range: 3 wk–5 y), circulating Mg concentrations were significantly elevated in the treatment 
groups in comparison to the placebo groups (WMD: 0.04 mmol/L; 95% CI: 0.02, 0.06) (Table 
1).  
Among participants receiving Mg supplementation with a median dose of 365 mg/d for a 
median duration of 12 wk, the overall population distribution shifted from a mean circulating Mg 
concentrations of 0.78 mmol/L at baseline to 0.83 mmol/L at post-treatment (Figure 2A).  
24-h Urine Mg excretion  
Approximately half (55%) of the 24 included trials examined 24-h urine Mg excretion (645 
11 
 
 
participants in treatment and 716 in control arms). After supplementing with a median dose of 
480 mg/d (range: 200–994 mg/d) for a median duration of 3 mo (range: 1 mo-1 y), 24-h urine 
Mg excretion was significantly elevated (WMD: 1.52 mmol/24h; 95% CI: 1.20, 1.83) compared 
to the placebos groups (Table 1). The mean urine Mg excretion in the treatment groups 
significantly increased by 32% (WMD: 1.24 mmol/24h; 95% CI: 0.94, 1.54) after treatment 
compared to baseline (Figure 2B).  
RBC Mg  
Nine trials examined RBC Mg, with 213 participants receiving Mg supplements and 208 
receiving placebos. After Mg supplementation with a median dose of 320 mg/d (range: 250–600 
mg/d) for a median duration of 2 mo (range: 3 wk–5 y), RBC Mg was significantly higher in the 
treatment groups than placebo groups (WMD: 0.12 mmol/L; 95% CI: 0.03, 0.20) (Table 1). A 
similar dose of 300 mg/d was used in all these 9 trials, which could not allow us to examine the 
dose-response relationship for RBC Mg. 
Ionized Mg  
Only 5 trials assessed ionized (intracellular) Mg; 3 in serum, 1 in plasma, and 1 in whole 
blood. Two trials evaluated ionized Mg in muscles. Overall, circulating ionized Mg 
concentrations were not significantly increased among 111 participants who received Mg 
supplements at a median dose of 320 mg/d (range: 197–360 mg/d) for 2 mo (range: 1–6.5 mo) 
compared to 107 participants who received placebos (WMD: 0.004 mmol/L, P=0.58). Two 
individual studies measured muscle ionized Mg; no significant differences between treatment 
and placebo groups were observed (23, 24).  
Other Mg biomarkers in blood, urine, or other specimens 
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As only a few trials examined intravenous (IV) Mg load, Mg balance, Mg retention, and 
mononuclear Mg, insufficient data were available for a meta-analysis of these biomarkers (Table 
1). 
      Mg in other tissues such as intracellular (4 trials), muscle (2 trials), feces (2 trials), hair (1 
trial), saliva (1 trial), and brain tissue (1 trial) were also assessed. Among these biomarkers, only 
fecal Mg concentrations were significantly elevated compared with placebo group after 
supplementation; the SMD based on 2 trials was 3.57 (95% CI: 1.59, 5.56) (Table 1). In 
addition, two trials evaluated muscle Mg concentrations, but no significant changes in this 
biomarker were observed (WMD: -0.20 mmol/L; 95% CI: -0.50, 0.10). 
Other Mg status-related biomarkers 
Among circulating and urine calcium, sodium, and potassium (Table 1), only urine calcium 
excretion was significantly increased by Mg supplementation to 0.40 mmol/24h (95% CI: 0.08, 
0.72; n=5 trials). The median Mg dose administered was 360 mg/d (range: 320–485 mg/d) for 16 
wk (range: 7 wk–6 mo). Three trials also evaluated the changes of PRA and plasma PTH; no 
significant differences between intervention and placebo arms was observed. 
      For all above analyses, no significant publication bias was detected by either Egger’s test or 
Begg’s test (all P-values >0.05).  
Dose- and time-dependent responses of circulating and urine Mg concentrations        
Figure 3 (A & B) shows nonlinear dose- and time-responses of circulating Mg to Mg 
supplementation (all P- nonlinearity <0.0001). Based on data from 41 eligible trials, circulating 
Mg concentrations appeared to increase immediately after supplementation and gradually 
reached a plateau concentration at a dose of approximately 300 mg/d (range: 300-994mg/d) and 
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at a duration of 20 wk (range: 20-52 wk).  
      As shown in Figure 3 (C & D), urine Mg excretion increased during the first 5 wk of 
supplementation, and then slowly reached a maximal steady-state at a dose of approximately 400 
mg/d elemental Mg, and after about 40 wk.  
Heterogeneity  
Between-study heterogeneity was high for circulating Mg, RBC Mg, urine Mg, and ionized 
Mg; all P-values from Q-tests were <0.0001 (all I2>80%) (Table 1). Sensitivity analysis showed 
that the overall results were robust and no single study affected the meta-analytic estimate by 
more than 5%. 
      Although no significant heterogeneity was observed by specific supplement formulation 
(Figure 4), circulating Mg concentrations in response to inorganic Mg salt were 4 times higher 
than the response to organic Mg salt (P-interaction=0.006). The WMD of circulating Mg for 
inorganic and organic was 0.07 mmol/L (95% CI: 0.03, 0.10) and 0.015 mmol/L (95% CI: 0.002, 
0.029), respectively. Additionally, a larger WMD for circulating Mg was observed in the ≥ 65 y 
subgroup than <65 y subgroup, although the difference was not statistically significant. 
      To examine the relation between baseline Mg status and circulating and urine Mg responses, 
we stratified all eligible trials into four subgroups by baseline circulating Mg concentrations (< 
0.77, 0.77–0.79, 0.80–0.86, and ≥ 0.87mmol/L) and four subgroups by baseline 24-h urine Mg 
excretion (< 3.15, 3.15–3.63, 3.64–4.62, and ≥ 4.63 mmol/24h). We found that high baseline 
circulating Mg concentrations were associated with less of an increase in circulating Mg by 
supplementation, and greater 24-h urinary Mg excretion (Figure 5 A & C) (both P-linearity 
<0.05). Baseline 24-h urine Mg excretion was positively and significantly associated with 
changes in urine Mg excretion (P-linearity=0.03) (Figure 5 D), but not changes in circulating 
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Mg concentrations in response to supplementation (P=0.95) (Figure 5 B).        
Quality of trials 
Due to insufficient information in the descriptions of included articles, only 21.1% seemed to 
have adequate sequence generation and 7.9% had low risk of bias in allocation concealment 
(Supplemental Figure 1). Sample sizes of included trials were small, ranging from 13 to 155 
participants. High quality studies accounted for 71.0% of the included trials. However, neither 
study quality nor sample size substantially affected biomarker responses to Mg supplements 
(Figure 4).  
DISCUSSION 
In this meta-analysis of 48 RCTs examining a total of 35 Mg biomarkers, circulating and 
urine Mg, the most frequently measured biomarkers, were significantly increased by Mg 
supplementation in a dose- and time-response manner. Effect modification by baseline 
circulating Mg concentrations, and inorganic vs. organic formulation of Mg supplement type was 
observed. This investigation provides the most comprehensive estimates to-date of the 
relationships between Mg biomarkers and Mg supplementation, and for the first time to our 
knowledge, the time-response of Mg biomarkers to supplementation in generally healthy 
populations.  
      In our meta-analysis, an elevation of 6% (0.05 mmol/L) in circulating Mg and of 32% (1.29 
mmol/24h) in urine Mg was observed in response to varied doses of oral Mg supplementation. 
Assuming a conservative cut-off level of serum Mg < 0.70 (or < 0.75 mmol/L) for defining Mg 
insufficiency (6), Mg supplementation substantially reduced the prevalence of insufficiency from 
26 to 2.1%, (or from 39 to 12%). Our analysis of 48 trials builds on and expands on findings of 
an earlier systematic review (22 trials) in which Mg supplementation increased circulating Mg 
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concentrations by 0.03 mmol/L and urinary Mg excretion by 1.82 mmol/24h (25). Altogether, 
this evidence suggests that Mg supplementation may reduce the risk of cardiovascular diseases 
(CVD), as previous meta-analyses of prospective studies have found that higher concentrations 
of circulating Mg are associated with lower CVD risk (10, 11). In addition, low 24-h urine Mg 
excretion was independently associated with a 40% higher risk of CVD incidence in a 
prospective population-based study (26).   
      Our novel dose- and time-response analyses revealed a maximal response of circulating Mg 
to oral supplementation at a dose ≥ 300 mg/d, and showed that at least 20 wk of Mg 
supplementation are required to achieve this steady-state concentration. Consistent with these 
findings, previous pharmacokinetic research indicated a relatively slow process of Mg 
equilibrium in humans with a half-life of >1000 h (≈ 6 wk) (27). Urine Mg achieved its highest 
levels at doses of ≥ 400 mg/d, and required a longer duration of supplementation, 30–40 wk. 
Give the observed dose- and time-dependent responses, circulating and urine Mg may be 
clinically useful biomarkers underlying Mg homeostasis in the human body.      
      Our analysis revealed important heterogeneity by baseline circulating Mg concentrations: we 
observed that high baseline circulating Mg concentrations were associated with less of an 
increase in circulating Mg by Mg supplementation, and greater 24-h urinary Mg excretion. If 
baseline circulating Mg concentrations ≥ 0.87 mmol/L, a concentration level with the normal 
range, Mg supplementation did not result in significant changes in circulating Mg concentrations, 
but substantial increase in urine Mg excretion. In fact, minimal to no responsiveness of 
circulating Mg concentrations and elevated urinary Mg excretion to Mg supplementation was 
observed among participants with normal Mg status, as objectively assessed by the gold standard 
Mg loading test (28, 29). Taken together, the results support the notion that circulating Mg and 
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24-h urinary excretion Mg may provide meaningful information about underlying Mg status, and 
provide new evidence that circulating Mg concentrations above currently defined clinical 
thresholds for hypomagnesemia may be appropriate for defining sufficient Mg status.  
       Our heterogeneity analyses also revealed, for the first time, that circulating Mg 
concentrations exhibit a significantly greater increase to inorganic Mg supplements than to 
organic supplements. The formulation of Mg is a key factor in its bioavailability. Previous work 
showed that organic Mg salts were more bioavailable than inorganic Mg salts supplements in 
animals (30) due to the limited solubility of inorganic Mg in the intestine (31, 32), a finding that 
seems to be contrary to our results. However, circulating concentrations of Mg in the inorganic 
supplement groups were lower than in the organic supplement groups, which may partially 
explain these findings. Our additional comparisons for different chemical formulations of oral 
Mg supplements, including Mg(OH)2, MgO, MgCl2, citrate, aspartate, and pidolate Mg, did not 
show significantly different responses of circulating Mg concentrations and urine Mg excretion. 
These findings are consistent with evidence from bioavailability experiments, showing that 
various Mg salts were nearly equivalent in their ability to increase circulating and urine Mg (30, 
33, 34).  
      Recently, ionized Mg has been proposed as a potentially useful biomarker of the biologically 
active portion of Mg in human (35). The limited numbers and small sample sizes of included 
trials investigating ionized Mg might partially explain the null pooled effect of Mg 
supplementation on ionized Mg. Also, vastly different assay methods and specimens used in 
trials may lead to large variance in the measurements of ionized Mg, making these estimates 
potentially inappropriate for meta-analysis.   
      Other tissue Mg concentrations such as muscle, saliva, hair, fecal, and brain tissues were also 
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reported in some trials. However, sensitivity of these biomarkers to Mg supplementation requires 
more data. Co-existence of secondary electrolyte abnormalities may play a key role in the 
clinical features of Mg depletion (36). For instance, calcium, potassium, and sodium in blood and 
urine were frequently assessed, and urine calcium concentrations appear to be more sensitive to 
Mg supplementation than others based on the present analysis. Despite some biological evidence 
suggesting that hypomagnesemia may interfere with the hypocalcaemia-induced PTH release 
(37, 38), our analysis based on 3 RCTs showed that Mg supplementation did not significantly 
affect PTH concentrations. 
Our meta-analysis has several strengths. Our quantitative assessment was based on data 
from RCTs largely of high-quality, which excluded open-label and one-arm trials, thereby 
minimizing selection bias and other biases. Our comprehensive search strategy make it unlikely 
that any major published trials were missed. The quality of all trials were formally evaluated by 
AHRQ criteria and Jada score to assess the influence of overall trial quality on the results. We 
also systematically reviewed both direct and indirect Mg-status related biomarkers, and 
addressed dose- and time-response of Mg biomarkers to Mg supplementation for the first time.  
      Several limitations warrant consideration. First, although a large number of randomized trials 
were included in our meta-analysis, few trials for biomarkers other than circulating and urine Mg 
was available, such as ionized Mg, and Mg in muscle, saliva and other tissues. Second, the 
presence of substantial between-study heterogeneity in the main meta-analyses could add 
uncertainty to estimates. However, we conducted several subgroup analyses stratified by many 
pre-specified factors, such as baseline Mg status, and organic vs. inorganic formulation, which 
contributed to significant heterogeneity of results. Third, trials with larger sample sizes and 
longer durations are clearly lacking. Fourth, influence by inadequate sequence generation and 
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allocation concealment as well as compliance could not be assessed due to a lack of relevant 
information in most of included RCTs. Finally, as in any meta-analysis of published results, 
publication bias is possible, although we did not find any evidence of publication bias based on 
Egger’s or Begg’s tests. 
      In conclusion, this meta-analysis of 48 RCTs showed that circulating Mg concentrations and 
24-h urine Mg excretion significantly responded to oral Mg supplementation in a dose- and time-
dependent manner. High baseline circulating Mg concentrations were associated with less or no 
changes in circulating Mg concentrations and a greater response of urine Mg excretion by Mg 
supplementation, consistent with gold-standard Mg loading test findings. Altogether, these 
findings support the notion that circulating Mg and 24-h urinary excretion Mg may provide 
meaningful information about underlying Mg status, and provide new evidence that a relatively 
high threshold level of circulating Mg concentrations, well above currently defined clinical 
thresholds for hypomagnesemia may be appropriate for defining sufficient Mg status. Our 
findings also directly inform the design of future Mg supplementation trials. Future well-
designed, adequately powered RCTs of Mg supplementation on intermediate and clinical 
endpoints are warranted to elucidate the potential role of Mg biomarkers for clinical risk 
assessment and population health. 
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TABLE 1. Overall weighted mean differences (WMDs/SMDs) of Mg biomarkers (treatment versus control 
groups) after oral Mg supplementation in 48 RCTs  
Biomarkers 
n of studies (n of 
participants in 
placebo/treatment) 
Pooled effect sizes,  
WMD (95% CI) 
P-values for 
 WMD/SMD 
Measures of 
heterogeneity, I2, % 
P-values for  
heterogeneity 3   
Mg Biomarkers      
  Serum Mg, mmol/L     29 (705/683)      0.05 (0.02, 0.07) < 0.0001 98.60 < 0.0001 
  Plasma Mg, mmol/L     12 (236/270)      0.03 (0.01, 0.05) < 0.0001 85.90 < 0.0001 
  Serum/plasma Mg, mmol/L 1     41 (941/953)      0.04 (0.02, 0.06)     < 0.0001 98.10  0.003 
  RBC Mg, mmol/L       9 (416/426)      0.12 (0.03, 0.20) 0.006 91.50 < 0.0001 
  Mononuclear Mg 2       4 (292/236)     0.08 (-0.22, 0.38)        0.60   0.00          0.54 
  Blood Ionized Mg, mmol/L       5 (214/222)    0.004 (-0.011, 0.019)        0.58 94.60 < 0.0001 
  24-h Urine Mg, mmol/24h 24 (1656/1527)      1.52 (1.20, 1.83) < 0.0001 96.90 < 0.0001 
  Muscle Mg, mmol/100g      2 (118/118)    -0.20 (-0.50, 0.10) 0.08 35.30 0.21 
  Muscle Ionized Mg, mmol/L          2 (50/50)    -0.01 (-0.05, 0.03) 0.32 47.90 0.17 
  Intracellular Mg 2      4 (126/136)    -0.39 (-1.51, 0.72) 0.49 86.50 < 0.0001 
  Fecal Mg 2         2 (80/80)       3.57(1.59, 5.56) < 0.0001 87.10 < 0.0001 
Mg Status-related Markers      
  Blood Ca, mmol/L 12 (560/617)   0.01 (-0.01, 0.03) 0.17 82.90 < 0.0001 
  Blood K, mmol/L   8 (340/385)   0.08 (-0.14, 0.31) 0.47 87.20 < 0.0001 
  Blood Na, mmol/L   6 (184/227)   0.13 (-0.73, 0.99) 0.76 34.80 0.18 
  PTH, pg/mL   3 (134/140)   1.13 (-10.4, 12.7) 0.85 84.80   0.001 
  PRA 2     3 (72/113)   0.03 (-0.48, 0.53) 0.91 11.40 0.32 
  24-h Urine Ca, mmol/24h   5 (428/334)    0.40 (0.08, 0.72) 0.02 81.30 < 0.0001 
  24-h Urine K, mmol/24h   7 (484/425)   2.67 (-1.16, 6.51) 0.17 52.90 0.05 
  24-h Urine Na, mmol/24h   7 (472/413) 2.54 (-9.80, 14.87) 0.69 77.40 < 0.0001 
1 Independent trials with either serum or plasma Mg concentrations were pooled together.  
2 The pooled effect was SMD because the units varied among studies. 
3   P-values were calculated for testing the between-study heterogeneity. 
   Abbreviations: PTH, Parathyroid Hormone; PRA, Plasma Renin Activity; RBC, Red Blood Cell; RCT, Randomized Controlled Trial;    
   SMD, Standard Mean Difference; WMD, Weighted Mean Difference. 
        
    
   
 
 
 
FIGURES LEGENDS 
FIGURE 1. Flow chart of study selection of eligible 48 RCTs for the meta-analysis. 
Abbreviations: Ca: calcium; IV: intravenous; K: potassium; Mg: magnesium; Mg2+: ionized Mg; 
Mg2+/Mg: ratio of serum ionized Mg to total serum Mg; Na: sodium; PTH: Parathyroid 
Hormone; PRA: Plasma Renin Activity; RBC: red blood cell, RCT: randomized controlled trial.  
FIGURE 2. Distributions of circulating Mg concentrations (A) and 24-h urine Mg excretion (B) 
among participants in the treatment groups before and after Mg supplementation.  
FIGURE 3. Circulating Mg concentrations (A, B) and 24-h urine Mg excretions (C, D) in 
response to the doses (A, C) or durations (B, D) of Mg supplementation. The relations were 
fitted by using restricted cubic spline curves and the 95% CIs shown as the gray shaded regions.   
FIGURE 4. Forest plots of weighted mean differences (WMDs) and their 95% confidence 
intervals (95% CIs) of responses of circulating Mg concentrations and 24-h urine Mg excretion 
to Mg supplementation compared with placebo stratified by age, sex, ethnicities, types of Mg 
supplements (compound formulation and salt type), cardiometabolic health status of participants, 
trial sample size, and quality of trials. Closed squares indicate the point estimates of WMDs from 
random-effects meta-analysis; horizontal bands represent the 95% CIs. ncirculating Mg: number of 
the included trials with available data on circulating Mg concentrations; nurine Mg: number of trials 
with available data on 24-h urine Mg excretion; Pcirculating Mg and Purine Mg: P-values for 
interactions between Mg supplementation and each of stratified factors on circulating Mg 
concentrations and 24-h urine Mg excretion, respectively; EP: Europeans; North A: North 
Americans; Latin A: Latin Americans; healthy and unhealthy status indicate participants with 
and without history of diabetes mellitus, cardiovascular diseases, or hypertension. 
FIGURE 5. Weighted mean differences and their 95% CIs of responses of circulating Mg 
 
 
 
concentrations (A, B) and 24-h urine Mg excretions (C, D) to Mg supplementation compared 
with placebo stratified by baseline circulating Mg concentrations (A, C) and urine Mg excretions 
(B, D). 
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Supplemental Table 1.  Characteristics of trials included in the meta-analysis 
 
Study 
 
Age, y 
Sex， 
%men 
Formulation; 
Dosage; Duration 
nT/nP1, 
Design 
 
Participants 
 
Concomitant 
 
Biomarkers Baseline dietary Mg 
Quality 2, 
Compliance 
 
 
Zemel, 1990, 
USA (1) 
 
 
 
Range: 20-
69 
 
 
Mixed, 
86% 
 
 
Mg aspartate; 
40mmol/d;3 
mo 
 
 
 
7/6, Parallel 
Uncomplicated 
mild-to-moderate 
essential 
hypertension and 
normal renal 
function 
 
Off all 
antihypertensi
ve medication 
for ≥ 3 mo 
 
 
Serum: Ca, Mg, K, Na; 24-h urinary 
Mg: Ca, Mg, K, Na; Erythrocyte 
intracellular: Mg; PRA 
 
 
 
NR 
 
 
 
3, 97% 
 
Facchinetti, 
1991, Italy (2) 
 
Range: 24-
39 
 
Women, 
0% 
Mg pyrrolidone 
carboxylic; 
360mg/d;3 mo (14 d 
per mo) 
 
14/14, 
Parallel 
 
Premenstrual 
syndrome 
 
None 
 
Plasma, erythrocyte, lymphocytes, 
polymorphonuclear Mg 
 
NR 
 
4, NR 
Desbiens, 
1992, USA (3) Range: 22-76 
Mixed, 
44% 
MgO; 362mg/d & 
724mg/d;1 mo 
16/18/14, 
Parallel Healthy None Serum Mg, Mononuclear Mg NR 3, NR 
Ferrara, 1992, 
Italy (4) 
 
Range: 40-
60 
Mixed, 
57% 
Mg pidolate; 
15mmol/d;6 mo 
 
7/7, Parallel Mild to moderate hypertension 
 
None Serum Na, K, Ca, and Mg; Urinary Na, K, Ca, and Mg 
 
NR 
 
3, NR 
Bashir, 1993, 
USA (5) 
 
Range: 42-
73 
Mixed, 
48% 
MgCl2; 
15.8mmol/d;6 
wk 
21, 
Crossover 
Stable congestive 
heart failure 
Diuretic 
therapy 
Serum Mg, Na, and K; Urinary Mg 
and K 
 
NR 
 
4, NR 
Pulm-Wirell, 
1994, 
Sweden (6) 
 
Range: 20-
59 
Mixed, 
62% 
Aspartate 
hydrochloride; 
15mmol/d;2 mo 
21/18, 
Crossover 
Untreated 
hypertension 
Only lifestyle 
intervention 
Serum Mg and K; Urinary Mg, K, 
and Na; Muscle: Mg, K 
 
NR 
 
4, NR 
Witteman, 
1994, 
Netherlands (7) 
 
Range:  
35-77 
 
Women, 
0% 
 
Mg aspartate-HC1; 
485 mg/d;6 mo 
 
47/44, 
Parallel 
 
Mild to moderate 
hypertension 
Not on 
antihypertensi
ve medication 
Serum: Ca, Mg 
24-h urinary: Ca, Mg, K, Na 
Plasma: PTH 
T: 330 ± 54 
P: 333 ± 80 
mg/d 
 
4, T: 91% 
P: 88% 
 
Eibl, 1995, 
Austria (8) 
 
Mean: 58 
 
Mixed, 
50% 
Mg citrate; 
365mg/d; 3 mo 
 
18/20, 
Parallel 
 
Type 2 diabetes 
 
None 
 
Serum Mg, Urinary Mg 
 
NR 
 
4, NR 
Eriksson, 
1995, 
Finland (9) 
 
NIDDM: 43 
± 2 
IDDM: 61±2 
 
 
NR 
 
NR; 600mg/d;90 d 29 NIDDM 27 IDDM, 
Crossover 
Non-insulin- 
dependent or 
insulin-dependent 
diabetes 
Insulin, 
diabetic drug 
& lifestyle 
intervention 
 
 
Plasma Mg and Urinary Mg 
 
 
NR 
 
 
4, NR 
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Study 
 
Age, y 
Sex， 
%men 
Formulation; 
Dosage; Duration 
nT/nP 1, 
Design 
 
Participants 
 
Concomitant 
 
Biomarkers Baseline dietary Mg 
Quality 2, 
Compliance 
Itoh, 1996, 
Japan (10) 
 
Mean: 64 Mixed, 50% 
Mg(OH)2; 411gm/d 
women, 548mg/d 
men;4 wk 
23/10, 
Parallel 
 
Healthy 
 
None Serum: Mg, K Ca, Na; Urinary Mg, Na, K, PRA 
P: 222 ± 17 
T: 229 ± 23 
mg/d 
 
3, NR 
Sanjuliani, 
1996, Brazil 
(11) 
 
Range: 36-
65 
 
Mixed, 88% MgO; 600mg/d;6 wk 
15, 
Crossover 
Mild to moderate 
primary 
hypertension 
 
None RBC Na, Mg, Ca, K; Urinary Na, PRA 
 
NR 
 
4, NR 
 
Costello, 
1997, USA 
(12) 
 
 
Range:  
31-77 
 
 
Men, 100% 
 
Mg lactate; 249.6 
mg/d;3 mo 
 
 
9/9, Parallel 
 
 
Healthy 
 
 
None 
Serum Mg, RBC Mg, fractional 
urine Mg, IV load, classification of 
percent magnesium retention, 
Serum, Plasma Mg ultrafiltrates 
P: 320 ± 22 
T: 311 ± 18 
mg/d 
 
 
2, 87% 
Sacks, 1997, 
USA (13) 
 
Mean: 38 Women, 0% 
Mg lactate; 
336mg/d;16 wk 
48/102, 
Parallel 
 
Healthy 
 
None 
 
Urinary Mg, Ca, K, Na 
T: 234 ± 69 
P: 238 ± 88 
mg/d 
 
3, good 
de Valk, 
1998, 
Netherlands (14) 
 
Mean: 63 Mixed, 56% 
Mg aspartate-HCl; 
15mmol/d;3 mo 
25/25, 
Parallel 
 
Type 2 diabetes 
 
Insulin Plasma Mg, Ca, Erythrocyte, Mg, Urinary Mg 
 
NR 
 
3, ≥80% 
 
Lima, 1998, 
Brazil (15)  
 
Range:  
30-69 
 
Mixed, 
25% 
MgO; 20.7 & 
41.4mmol/d;30 d 
 
35/39/54, 
Parallel 
 
Type 2 diabetes 
Diet and 
hyperglycemic 
medicine 
 
Plasma, Mononuclear, Urinary Mg 
 
NR 
 
3, NR 
 
Walker, 
1998, UK 
(16)  
 
Range:  
18-25 
 
Women, 
0% 
 
MgO;200mg/d;2 
mo 
 
35/36, 
Crossover 
Severe of 
premenstrual 
symptoms 
 
None 
 
Urinary Mg 
 
NR 
 
4, NR 
 
Ellen, 1998, 
Germany (17) 
 
Mean: 23 
 
Mixed, 
80% 
 
MgO; 300;3 wk 
 
10/10, 
Parallel 
Athletes with low- 
normal serum 
magnesium 
Exercise 
training and 
diet 
Serum Mg, Erythrocyte Mg, 
Platelete Mg, Mononuclear 
leukocytes Mg, Muscle Mg2+ 
 
NR 
 
3, NR 
Hagg, 1999, 
Sweden (18) 
 
Range:  
23-56 
Mixed, 
46% 
Mg(OH)2; 20-30 
mmol/d;12 mo 
15/13, 
Parallel 
 
Type I diabetes Acting insulin medicine 
 
Urinary Mg, Serum Mg 
 
NR 
 
5, NR 
 
Warry,  1999, 
French (19) 
 
Mean ± 
SD: 
23.7±4.
5 
 
Men, 
100% 
Mg lactate; 
12mmol/d Mg and 
5mg pyridoxin;1 mo 
 
15/15, 
Parallel 
 
 
Healthy 
 
 
None 
 
Plasma: Mg, Mg2+ ; 24h urinary Mg; 
RBC: Mg; muscle Mg2+ & Brain 
tissue Mg2+; Blood: Ca, Na, K 
 
 
NR 
 
 
3, good 
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Study 
 
Age, y 
Sex， 
%men 
Formulation; 
Dosage; Duration 
nT/nP 1, 
Design 
 
Participants 
 
Concomitant 
 
Biomarkers Baseline dietary Mg 
Quality 2, 
Compliance 
Zorbas, 
1999, 
Greece (20) 
 
 
Mean: 25 
 
Men, 
100% 
 
Mg lactate; 23mg/kg 
body weight;364 d 
 
10/10, 
Parallel 
Healthy and 
hypokinetic 
athlete 
 
 
None 
 
Urinary Mg, fecal Mg, Serum Mg, 
Mg balance 
hypokinetic: 627 
mg/d 
healthy: 662 
mg/d 
 
 
2, NR 
Walker, 2002, 
UK (21) 
 
NR Women, 0% 
MgO; 200, 350, 
500mg/d;2 mo 
47/40/41, 
Crossover 
Premenstrual 
syndrome 
 
None 
 
Urinary Mg 
 
NR 
 
4, NR 
 
Mooren, 
2003, 
Germany (22) 
 
 
Range: 
21-30 
 
Men, 
100% 
 
NR; 15mmol/d;60 
d 
 
10/10, 
Parallel 
 
 
Healthy 
 
 
None 
Intracellular Mg in erythrocytes, 
and free Mg2+ in erythrocytes, 
extracellular Mg in serum and 
extracellular Mg2+ in blood 
 
 
NR 
 
 
2, NR 
Rodr´Iguez- 
Mor´an, 2003, 
Mexico (23) 
 
 
Mean: 57 
 
 
NR 
 
MgCl2;2.5g/d;16 wk 
 
32/31, 
Parallel 
 
 
Type 2 diabetes 
 
Lifestyle 
intervention 
 
 
Serum Mg, Ca, Ca/Mg 
 
 
NR 
 
5, P: 88.6% 
T: 91.4% 
 
Walker, 2003, 
UK (24) 
 
 
Mean: 25 
 
Mixed, 
35% 
Mg citrate, Mg amino 
acid chelate, MgO; 
300mg/d;60 d 
 
10/10, 
Parallel 
 
Healthy 
 
None 
 
Plasma Mg, Salivary Mg 
 
Mean: 268 
mg/d 
 
5, NR 
Závaczki, 
2003, 
Hungary (25) 
 
Mean: 29 
 
Men, 
100% 
 
Mg orotate; 
196.8mg/d;90 d 
 
10/10, 
Parallel 
 
Healthy 
 
None 
 
Serum Mg, Mg2+ 
 
NR 
 
2, NR 
De Leeuw, 
2004, 
Belgium (26) 
 
Range: 
17-67 
Mixed, 
56% 
Mg gluconate; 
300mg/d;5 y 
49/48, 
Parallel 
 
Type 2 diabetes 
 
None 
 
Serum Mg, RBC Mg 
 
NR 
 
2, NR 
Pokan, 2006, 
USA (27) 
 
> 40 Men, 100% 
Mg citrate; 
365mg/d;6 mo 
28/25, 
Parallel 
Stable coronary 
artery disease 
Regular 
medication, 
exercise and 
 
Intracellular Mg in sublingual 
epithelial cell 
 
NR 
 
4, NR 
Rodríguez, 
2008, 
Mexico (28) 
 
> 60 Mixed, 48% 
MgCl2;450mg/d;12 
wk 
12/11, 
Parallel 
Type 2 diabetes 
and depression 
 
None 
 
Serum Mg 
 
NR 
 
5, NR 
Almoznino- 
Sarafian, 2009, 
Israel (29) 
 
Mean: 72 Mixed, 53% 
Mg citrate; 
300mg/d;5 wk 
16/16, 
Parallel 
 
Heart failure 
Insulin,statins 
hypoglycemic 
drugs, etc. 
 
Serum Mg, intracellular Mg 
 
NR 
 
2, NR 
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Age, y 
Sex， 
%men 
Formulation; 
Dosage; Duration 
NT/NP1, 
Design 
 
Participants 
 
Concomitant 
 
Biomarkers Baseline dietary Mg 
Quality 2, 
Compliance 
Lee, 2009, 
Sounth 
Korea (30) 
 
Range: 30-
60 
Mixed, 
50% 
MgO;300mg/d;12 
wk 
75/80, 
Parallel 
 
Overweighted 
 
None 
 
Serum Mg, hair Mg 
 
NR 
 
5, NR 
Romero, 
2009, 
Mexico (31) 
 
 
Range: 40-
75 
 
Mixed, 
48.1% 
 
MgCl2;450mg/d;4 
mo 
 
42/40, 
Parallel 
Diabetic 
hypertension and 
low serum 
magnesium 
Captopril & 
lifestyle 
intervention 
 
 
Serum: Ca, K, Na, Mg 
 
 
NR 
 
 
5, NR 
Aydın, 2010, 
Turkey (32) 
 
Mean: 53 Women, 0% 
Mg citrate; 205 
mg/d;30 d 
10/10, 
Parallel 
postmenopausal 
women 
 
None 
 
Serum Ca, Mg, PTH 
 
NR 
 
2, NR 
 
Kazaks, 2010, 
USA (33) 
 
Range: 21-
55 
 
Mixed, 
44% 
Mg citrate; 
340mg/d;6.5 
mo 
 
28/27, 
Parallel 
 
Mild to moderate 
asthma 
Beta-agonists 
or inhaled 
corticosteroids 
 
Serum Mg, Mg2+, erythrocyte Mg, 
IV Mg load 
P: 281 ± 26 
T: 296 ± 27 
mg/d 
 
4, T: 90.7% 
C: 92.5% 
 
Nielsen, 2010, 
USA (34) 
 
Range: 51-
85 
 
Mixed, 
22% 
 
Mg citrate; 
320mg/d;7wk 
 
46/49, 
Parallel 
 
Poor sleep quality 
 
None 
Urinary Mg, Ca 
Serum: Mg, Mg2+, Mg2+/Mg, 
Ca RBC: Mg 
 
NR 
 
3, NR 
Zorbas, 
2010, 
Greece (35) 
 
Mean ± SD: 
21.5 ± 3 
 
Men, 
100% 
MgCl2; 3mmol per 
kilogram body 
weight;364 d 
 
10/10, 
Parallel 
 
Healthy 
 
None 
 
Mg in Urine, Plasma, Muscle, Fecal 
 
Mean: 212 
mmol/d 
 
2, NR 
Chacko, 2011, 
USA (36) 
Mean ± SD: 
44 ± 13 
Mixed, 
71% 
Mg citrate; 
500mg/d;4 wk 
7/7, 
Crossover 
Healthy and 
overweighted 
 
None 
 
Serum Mg, Ca, PTH 
 
NR 
 
5, NR 
Romero, 
2011, 
Mexico (37) 
 
Range: 40-
65 
 
Mixed, 
59% 
 
MgCl2; 2.5g/d;3 
mo 
 
54/52, 
Parallel 
 
Healthy 
 
None 
 
Serum Mg 
 
NR 
 
5, NR 
Esfanjani, 
2012, Iran 
(38) 
 
Range: 18-
55 
Mixed, 
25% 
MgO; 300mg/d;12 
wk 
33/35, 
35/30, 
  Parallel   
 
Migraine 
 
No analgesics 
 
Serum Mg 
 
NR 
 
3, NR 
1 IV load test: intravenous load test; Mg2+: ionized Mg; NR: Not Report; nT: No. of participants in treatment, nP: No. of participants in placebo; P: Placebo; PTH: 
Parathyroid Hormone; PRA: Plasma Renin Activity; T: Treatment. 
2 Quality: The 5-point Jadad Score based on the description of randomization, double blinding and withdrawals. 
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Supplemental Figure 1. Quality of identified 48 trials in the meta-analysis. 
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